Navigation Links
Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
Date:11/9/2011

BOONTON, N.J., Nov. 9, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced positive top-line results of its Phase 2 clinical study evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in 93 postmenopausal women.  The study achieved its primary endpoint with statistical significance. The Phase 2 study was conducted by Unigene as part of an exclusive worldwide option and licensing agreement with GlaxoSmithKline (GSK).  

The primary objective of the study was to assess the change in bone mineral density (BMD) at the lumbar spine, a clinically validated predictor of fracture risk.  The study demonstrated once-daily treatment with 5mg of orally delivered PTH resulted in a statistically significant mean increase in BMD at the lumbar spine of 2.2 percent (p<0.001) at week 24 as compared to baseline.  

Ashleigh Palmer, President and CEO, stated, "We are delighted to report these positive Phase 2 results from our oral PTH program.  These results further validate Unigene's proprietary oral peptide drug delivery technology and, importantly, we have demonstrated that the oral delivery of PTH is possible, having successfully achieved proof-of-concept.  We now believe we have the opportunity to address an important unmet medical need.  Unigene's Peptelligence™ platform continues to lead the industry, and we are committed to ensuring our distinctive core competence dominates the growing peptide sector, establishing Unigene as the peptide partner of choice."

Secondary endpoints in the Phase 2 study evaluated an open label comparator arm of injectable Forsteo® (teriparatide), an approved treatment for osteoporosis, and placebo to assess the changes in BMD at the lumbar spine at 24 weeks.  The Forsteo® comparator arm showed a
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, Inc. ... on gynecologic disease, announced today that investors including ... Birchview Fund LLC and several Vermillion directors have ... shares of Vermillion,s common stock and warrants to ... a private placement.  Under the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... Lawrence, MA (PRWEB) December 19, 2014 ... flow MRLAFMQ test for the Detection of Aflatoxin M1 ... test to receive independent third party validation. The peer ... Science Unit of the Institute for Agricultural and Fisheries ... Francis Group. , Aflatoxin B1, the most toxic ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... woundcare division of,Insense Ltd., today announced it has received ... Oxyzyme product in the treatment of,difficult and chronic wounds. ... one of the world,s leading wound care specialists, in ... The announcement was made at,the 3rd Congress of the ...
... June 6 Inverness Medical,Innovations, Inc. (Amex: IMA ... for the consumer and professional markets, today,announced that it ... & Medical Technology Conference being held June 11-12, 2008,at ... Jon Russell, Vice President,Finance, will present on Thursday, June ...
... June 6 DURECT Corporation,(Nasdaq: DRRX ) announced today that ... New York, NY., -- Needham & Company,s ... June 12th at 11:30 a.m. EDT. -- Leerink Swann,s Pain ... 12:45 p.m. EDT. -- Jefferies, 2nd Annual Healthcare Conference on ...
Cached Biology Technology:Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada 2
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... study sheds additional light on how erectile dysfunction (ED) ... uncovering the link between the two disorders, and may ... study, "Lack of Central Nitric Oxide Triggers Erectile Dysfunction ... Mayhan, and Kaushik P. Patel, Departments of Cellular and ...
... therapy in mice to shut down a gene that plays ... , The technique, detailed in an upcoming issue of Vision ... material called interfering RNA, which helps disable the gene. ... mutated versions of it are passed from generation to generation ...
... made his way out of Africa some 60,000 years ... He was accompanied by the bacterium Helicobacter pylori, which ... the bacterium spread throughout the entire world. This is ... led by Mark Achtman from the Max Planck Institute ...
Cached Biology News:Erectile dysfunction in diabetes is due to selective defect in the brain 2Erectile dysfunction in diabetes is due to selective defect in the brain 3Gene therapy for blindness clears hurdle in mice 2Out of Africa -- Bacteria, as well 2
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
...
... MW: 34.2kDa Formulation: 10mM HEPES, pH ... dithiothreitiol with 50% glycerol Properites: For ... Certificate of Analysis for individual lots ... followed by gel filtration and Mono-S ...
Antibody Purification Specificity: Antibody Purification ...
Biology Products: